Dr. Matthew Halpert holds a Ph.D from the University of Alabama and holds a faculty position at Baylor College of Medicine in Houston, Texas. Dr. Halpert is the Director of Research & Development at Medterra and is currently responsible for all its product related research and development.
These activities include performing pharmacological studies on CBD’s efficacy, while evaluating the latest peer reviewed publications on CBD. Matthew Halpert and John Malanca (https://unitedpatientsgroup.com/be_informed_be_well/) discuss his entry into the CBD market and some interesting observation and study results.
John Malanca talks through good, bad, and exciting in cannabis medicine in this discussion of CBD (https://unitedpatientsgroup.com/certified-products/) with Dr. Halpert. When the Farm Bill expanded access to cannabidiol, manufacturers’ interest exploded. However, in order to make honest claims, Dr. Halpert teamed with Medterra CBD to determine the real healing powers of this remarkable cannabinoid.
When Dr. Halpert, an expert in the field of immunology and inflammation was hired by Medterra, his professional interests centered around the quality, amount, and dosing of CBD as well as its functionality. Whether determined by double blind studies, studies in humans, dogs and/or on himself he engages in a frank discussion about his findings with John. He also confirms Baylor will enter the testing of CBD.
Dr. Halpert discusses the federal constraints around cannabis, its Schedule I status and how CBD testing remains erratic and difficult to distinguish. However, in dog studies, CBD showed remarkable action against osteoarthritis which continued to be effective long after the dosing stopped.
While Dr. Halpert has never worked with THC, he agrees that the entourage effects require serious scientific analysis and without the science, he fears this remarkable plant will sit on the shelves as a supplement, with the understanding of its quality and the tragic loss of our knowledge of its medical benefits.
source
